Literature DB >> 20479394

Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.

Filippo Bellati, Chiara Napoletano, Ilary Ruscito, Marco Liberati, Pierluigi Benedetti Panici, Marianna Nuti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20479394     DOI： 10.1200/JCO.2010.28.6922

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.

Authors:  Dhara N Amin; Deepika Ahuja; Paul Yaswen; Mark M Moasser
Journal:  Mol Cancer Ther       Date:  2015-10-05       Impact factor: 6.261

2.  Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling.

Authors:  David J Klinke
Journal:  Mol Cell Oncol       Date:  2015-04-14

3.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Authors:  Holbrook E Kohrt; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Ferenc Scheeren; Debra Czerwinski; A Dimitrios Colevas; Wen-Kai Weng; Michael F Clarke; Robert W Carlson; Frank E Stockdale; Joseph A Mollick; Lieping Chen; Ronald Levy
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

4.  Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.

Authors:  Mark M Moasser
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

5.  Targeting HER2 by Combination Therapies.

Authors:  Ana Ruiz-Saenz; Mark M Moasser
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

6.  Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Authors:  Lisa A Carey; Donald A Berry; Constance T Cirrincione; William T Barry; Brandelyn N Pitcher; Lyndsay N Harris; David W Ollila; Ian E Krop; Norah Lynn Henry; Douglas J Weckstein; Carey K Anders; Baljit Singh; Katherine A Hoadley; Michael Iglesia; Maggie Chon U Cheang; Charles M Perou; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

7.  Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.

Authors:  Weijun Wang; Haiping He; Nagore I Marín-Ramos; Shan Zeng; Steven D Swenson; Hee-Yeon Cho; Jie Fu; Paul M Beringer; Josh Neman; Ligang Chen; Axel H Schönthal; Thomas C Chen
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

8.  Immune effects of trastuzumab.

Authors:  Marianna Nuti; Filippo Bellati; Valeria Visconti; Chiara Napoletano; Lavinia Domenici; Jlenia Caccetta; Ilaria Grazia Zizzari; Ilary Ruscito; Hassan Rahimi; Pierluigi Benedetti-Panici; Aurelia Rughetti
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207

Review 9.  Monoclonal antibodies in gynecological cancer: a critical point of view.

Authors:  Filippo Bellati; Chiara Napoletano; Maria Luisa Gasparri; Valeria Visconti; Ilaria Grazia Zizzari; Ilary Ruscito; Jlenia Caccetta; Aurelia Rughetti; Pierluigi Benedetti-Panici; Marianna Nuti
Journal:  Clin Dev Immunol       Date:  2011-12-26

10.  Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Authors:  Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki
Journal:  Breast Cancer Res       Date:  2015-05-23       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.